HCPLive Network
Latest Oncology Headlines
Thursday, November 20, 2014
By Christina Izzo
Adding 1-year of adjuvant trastuzumab to chemotherapy continues to demonstrate an improvement in overall survival (OS) and disease-free survival (DFS) for patients with early-stage HER2-positive breast cancer
Thursday, November 20, 2014
Evidence suggests a genetic basis for clinical response to cytotoxic T-lymphocyte antigen 4 blockade in melanoma, according to research published online Nov. 19 in the New England Journal of Medicine.
Thursday, November 20, 2014
For African-Americans, sickle cell trait is associated with an increased risk of pulmonary embolism, but not deep vein thrombosis, according to a study published online Nov. 13 in the Journal of Thrombosis and Haemostasis.
Thursday, November 20, 2014
By Silas Inman
Treatment with the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) has demonstrated promising clinical efficacy with lower toxicity across a variety of settings for patients with HER2-positive metastatic breast cancer when compared with standard therapies.
Thursday, November 20, 2014
By Adam Hochron
As hospitals around the country deal with the newly instituted readmission penalties many are having to look at how they will handle providing the same level of care without some of the money they counted on in the past.
Thursday, November 20, 2014
By Jane de Lartigue, PhD
Despite numerous reports of “miracle cures” for a select few patients treated with a variety of different anticancer therapies, drugs that failed to show improvement for a large number of patients have historically been considered failures and have been shelved.
Wednesday, November 19, 2014
By Andrew J. Roth
Juno Therapeutics, Inc, has filed a registration statement for an initial public offering of its common stock, as its early stage therapies continue to advance in clinical trials.
Wednesday, November 19, 2014
By Silas Inman
The FDA has granted MM-398 (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer
Wednesday, November 19, 2014
In metastatic melanoma, nivolumab improves overall and progression-free survival versus dacarbazine, and dabrafenib plus trametinib improves survival versus vemurafenib monotherapy, according to two studies published online Nov. 16 in the New England Journal of Medicine.
Wednesday, November 19, 2014
By Ravi A. Chandra, MD, PhD
Doctors are taught to think through medical decisions by listing a series of options, weighing the risks and benefits of each, and ultimately concluding on the superior option. This comparative maximization approach is drilled into us as medical students and residents.
Tuesday, November 18, 2014
By Tony Hagen
When Marcela V. Maus, MD, PhD, thinks of the challenge of bringing chimeric antigen receptor (CAR) therapies to market in the battle against cancer, she is reminded of the auto industry’s first days.
Tuesday, November 18, 2014
By Lauren Zoeller
Confusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding
Monday, November 17, 2014
For African-Americans, sickle cell trait is associated with increased risk of chronic kidney disease, according to a review published online Nov. 13 in the Journal of the American Medical Association. The research was published to coincide with the American Society of Nephrology's Kidney Week 2014, held from Nov. 11 to 16 in Philadelphia.
Monday, November 17, 2014
Molecular evidence indicates that eight probable/possible high-risk human papillomavirus types are biologically active, according to a study published in the December issue of The Journal of Pathology.
Monday, November 17, 2014
By Silas Inman
Frontline treatment with nivolumab significantly extended OS and PFS compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.
Sunday, November 16, 2014
By Silas Inman
The PD-1 inhibitor pembrolizumab significantly improved PFS by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab.
Thursday, November 13, 2014
Breast cancer patients who experience pain and swelling related to their treatment may find relief in acupuncture and exercise, new research suggests. The two studies have been published in the November issue of the Journal of the National Cancer Institute Monographs.
Thursday, November 13, 2014
Many American doctors may not support genetic testing in patients without a major family history of certain illnesses, suggests a new survey of physicians. The report appears in the Nov. 13 issue of the New England Journal of Medicine.
Thursday, November 13, 2014
Market forces are dramatically driving up the cost of some generic drugs, prompting US investigations into the pricing of what should be cheap alternatives to brand-name medications.
Thursday, November 13, 2014
In a study of 241 ,597 women who had breast conservation surgery for breast cancer, 23.6% needed a second operation. The report was published online Nov. 12 in JAMA Surgery.
Physician's Money Digest
Job growth, increasing consumer confidence, and lower gas prices will fuel moderate spending growth this holiday season, according to a new study.
Recently, the International Energy Agency (IEA) published a report on total global investments in one specific form of "energy" in 2012. It pegged investment in this form of energy at between $310 billion and $360 billion. What is it? The answer might surprise you.